Mammary fibroadenomas are the most common benign breast tumors, most do not show progressive growth, with about 80% entering a quiescent phase after the growth phase, 15% degenerating, and only 5% to 10% progressing.
The epithelial component of fibroadenoma has a very low risk of carcinogenesis, with a rate of 0.12% to 0.30%, and most carcinomas are lobular carcinomas in situ . The risk of breast cancer is slightly higher in patients with fibroadenoma than in the general population (1.48-1.70 times), and patients with atypical hyperplasia, first-degree relatives with breast cancer, or complicated fibroadenoma have a higher risk of breast cancer than patients with common breast fibroadenoma.
There are no drugs known to reverse or eliminate established fibroadenomas, but at best to slow their growth. Therefore, once a fibroadenoma has formed, it must be surgically removed to be eradicated. If surgery is not an option, you may choose to review the lump every 3 to 6 months to evaluate changes.